Gilead Sciences

Gilead Axes Phase III Magrolimab Trial Based on Disappointing Data
Gilead Axes Phase III Magrolimab Trial Based on Disappointing Data
BioSpace
Gilead Sciences
magrolimab
clinical trials
blood cancers
Flag link:
Gilead Sciences, after trial win, moves ahead with $247M settlement in HIV antitrust case
Gilead Sciences, after trial win, moves ahead with $247M settlement in HIV antitrust case
Fierce Pharma
Gilead Sciences
Teva Pharmaceutical
HIV
legal
antitrust
Flag link:
Could Gilead’s Trodelvy be the next TROP-2 therapy game-changer in NSCLC treatment?
Could Gilead’s Trodelvy be the next TROP-2 therapy game-changer in NSCLC treatment?
Clinical Trials Arena
Gilead Sciences
Trodelvy
TROP-2
non-small cell lung cancer
Flag link:
Kite publishes Phase II data for Yescarta in treating B-cell lymphoma
Kite publishes Phase II data for Yescarta in treating B-cell lymphoma
Clinical Trials Arena
Gilead Sciences
Kite Pharma
Yescarta
clinical trials
CAR-T
relapsed or refractory large B-cell lymphoma
Flag link:
Gilead unveils promising data from trial of combo therapy for lung cancer
Gilead unveils promising data from trial of combo therapy for lung cancer
Clinical Trials Arena
Gilead Sciences
Trodelvy
metastatic non-small cell lung cancer
Flag link:
Gilead-backed study warns IRA price negotiations could hit R&D harder than expected
Gilead-backed study warns IRA price negotiations could hit R&D harder than expected
Fierce Biotech
Gilead Sciences
Inflation Reduction Act
R&D
Flag link:
FDA Decisions 2023: Sandoz, Gilead Sciences and More
FDA Decisions 2023: Sandoz, Gilead Sciences and More
BioSpace
FDA
Sandoz
Novartis
Gilead Sciences
Pfizer
Neurocrine
Regeneron
Ipsen
Revance Therapeutics
Delcath Systems
Janssen
Galera Therapeutics
Biogen
Roche
Mesoblast
Taiho Oncology
Flag link:
Gilead's magrolimab once again placed on partial clinical hold, another setback for Forty Seven bet
Gilead's magrolimab once again placed on partial clinical hold, another setback for Forty Seven bet
Fierce Biotech
Gilead Sciences
MDS
magrolimab
clinical trials
AML
Flag link:
Gilead antibody drug shows signs of potential in early lung cancer
Gilead antibody drug shows signs of potential in early lung cancer
BioPharma Dive
Gilead Sciences
Trodelvy
Merck
Keytruda
lung cancer
Flag link:
Gilead, Tentarix collab to develop cancer, inflammatory disease therapies
Gilead, Tentarix collab to develop cancer, inflammatory disease therapies
Medical Marketing and Media
Gilead Sciences
Tentarix Biotherapeutics
cancer
inflammatory disease
Flag link:
Gilead inks $66M+ deal with Tentarix in oncology, inflammatory diseases
Gilead inks $66M+ deal with Tentarix in oncology, inflammatory diseases
Fierce Biotech
Tentarix Biotherapeutics
Gilead Sciences
oncology
inflammatory disease
Flag link:
FDA lifts clinical hold on Gilead's CAR-T as Arcellx sheds light on reason for patient death
FDA lifts clinical hold on Gilead's CAR-T as Arcellx sheds light on reason for patient death
Fierce Biotech
Gilead Sciences
Arcellx
CAR-T
cell therapy
FDA
Flag link:
ALX follows Gilead in axing CD47 blood cancer trials as data disappoint
ALX follows Gilead in axing CD47 blood cancer trials as data disappoint
Fierce Biotech
Gilead Sciences
ALX Oncology
blood cancer
clinical trials
anti-CD47
evorpacept
Flag link:
Arcus and Gilead terminate development for etrumadenant in prostate cancer
Arcus and Gilead terminate development for etrumadenant in prostate cancer
Clinical Trials Arena
Arcus Biosciences
Gilead Sciences
prostate cancer
etrumadenant
Flag link:
Gilead quarterly profit falls on COVID sales drop, legal settlement charge
Gilead quarterly profit falls on COVID sales drop, legal settlement charge
Reuters
Gilead Sciences
earnings
Flag link:
Gilead-backed cell therapy startup Kyverna adds fresh funds for new strategy
Gilead-backed cell therapy startup Kyverna adds fresh funds for new strategy
BioPharma Dive
Kyverna Therapeutics
lupus
Gilead Sciences
Treg cell therapy
Flag link:
Spotlight – Nash in 2023 and beyond
Spotlight – Nash in 2023 and beyond
EP Vantage
NASH
Boehringer Ingelheim
Zealand Pharma
Akero Therapeutics
Axcella Health
Eli Lilly
Pfizer
Ionis Pharmaceuticals
Cascade
AstraZeneca
Gilead Sciences
Novo Nordisk
Ascletis Pharma
MediciNova
Flag link:
Gilead unveils $6 million HIV and viral hepatitis initiative for Australian and Canadian indigenous communities
Gilead unveils $6 million HIV and viral hepatitis initiative for Australian and Canadian indigenous communities
Biopharma Reporter
Gilead Sciences
HIV
Australia
Canada
indigenous communities
Flag link:
J&J, GSK's ViiV tout switching study showing patients prefer their long-acting HIV med Cabenuva over Gilead rival
J&J, GSK's ViiV tout switching study showing patients prefer their long-acting HIV med Cabenuva over Gilead rival
Fierce Pharma
JNJ
GSK
ViiV
Gilead Sciences
HIV
Cabenuva
Biktarvy
Flag link:
Cognizant, Gilead Extend Service Agreement Worth $800M
Cognizant, Gilead Extend Service Agreement Worth $800M
Marketwatch
Cognizant
Gilead Sciences
information technology
Flag link:

Pages